Sanofi and Regeneron have received approval from the European Commission for their drug Dupixent as a treatment for atopic dermatitis.
The European Commission has granted marketing authorisation for Dupixent to be used as a treatment for adults with moderate to severe atopic dermatitis who are candidates for systemic therapy.
“Sanofi and Regeneron have received European regulatory approval for Dupixent in the treatment of moderate to severe atopic dermatitis.“
This human monoclonal antibody therapy is designed to specifically inhibit overactive signalling of two key proteins, IL-4 and IL-13, both major drivers of the persistent underlying inflammation in atopic dermatitis. It comes in a prefilled syringe and can be self-administered by a patient as a subcutaneous injection.
Dupixient was able to demonstrate its safety and efficacy in the LIBERTY AD clinical trial programme, which included nearly 3,000 patients.
Dr Elias Zerhouni, president for global research and development at Sanofi, said: "We are now focused on quickly making this important new treatment option available to people across Europe who live with this systemic disease."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical